Background and Aim Helicobacter pylori (H. pylori) and aspirin are the major causes of gastric injury, and eradication of H. pylori can restore mucosal injury such as gastric ulcer. The aim of the present study was to investigate the effects of low-dose aspirin on the healing process, determined by endoscopic features, after H. pylori eradication. Methods From 2001 to 2008, 12,887 patients underwent endoscopic examination at our hospital. From these, 100 patients with and 100 patients without H. pylori infection were analyzed to identify the endoscopic features characteristic of H. pylori-infected stomach. Based on these characteristic features, we observed the healing process of 89 patients not taking low-dose aspirin and 12 patients taking low-dose aspirin for 6 months, 1 year, and 5 years, which was successful in eradicating H. pylori. Results Diffuse redness (DR) of the fundic mucosa was the characteristic feature of H. pylori-infected stomach, whereas reddish streaks (RS) on the greater curvature of the antrum was the characteristic finding in non-infected stomach. In the no aspirin group, DR faded by 6 months and new expression of RS was observed 1 year after H. pylori eradication. In contrast, in the aspirin group, both fading of DR and the expression of RS were observed 5 years after eradication. Conclusion Low-dose aspirin delayed the early phase of the healing process in the gastric mucosa after H. pylori eradication.
Introduction
Long term Helicobacter pylori (H. Pylori) infection is one of the main causes of chronic active gastritis, gastric ulcer, duodenal ulcer, and possibly gastric carcinoma (1, 2) . A number of reports have shown microscopic improvement of gastric mucosa after H. pylori eradication; for example, chronic active gastritis, atrophic gastritis, nodular gastritis, and intestinal metaplasia (IM) were diminished by eradication (3, 4) . In addition, eradication of H. pylori led to a lower prevalence rate of secondary gastric carcinoma in patients with multiple gastric carcinomas at different time points (5, 6) and reduction of gastric mucosa-associated lymphoid tissue (MALT) lymphoma (7) (8) (9) (10) .
Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) are other factors that are known to contribute to gastro-duodenal mucosal injury. Although low-dose aspirin is a primary therapy advocated for the prophylaxis of cerebrovascular and cardiovascular diseases, it can cause significant gastrointestinal complications such as gastric ulcer bleeding (11) (12) (13) (14) (15) (16) (17) . However, the nature of the interaction between H. pylori infection and low-dose aspirin in vitro or in vivo has not been fully elucidated (18) . It has been reported that H. pylori eradication does not significantly promote healing of gastric and duodenal ulcers associated with long-term NSAIDs use in arthritis patients (19) . This result was supported by another study showing that H. pylori infection is associated with increased cyclooxygenase-2 (COX-2) expression in gastric antral mucosa of both NSAIDs users and nonusers, but not in gastric ulcer, in which the effect of NSAIDs use played a major role (20) .
It is controversial as to whether aspirin can have an additive effect on the conventional H. pylori eradication protocol, even though aspirin has been shown to suppress the growth of H. pylori in vitro (18, 20) . Thus, the interaction between aspirin and H. pylori infection has been discussed from the view-point of preventive effects of H. pylori eradication on aspirin-induced gastric ulcer disease or possibility of combination treatment of aspirin with conventional eradication method. There have been no reports, however, addressing the question how aspirin affects the healing process of the gastric mucosa after H. pylori eradication.
Although the accurate diagnosis of H. pylori infection just by endoscopic features without histological information is difficult, some papers have identified the specific endoscopic features to H. pylori-infected stomach. According to the Sydney system, diffuse redness (DR) of fundic mucosa is recognized as patchy erythema (21) and it was shown that DR of fundic mucosa was the characteristic feature in H. pylori-infected stomach and it disappeared after H. pylori eradication (22) . In contrast the endoscopic finding of reddish streaks (RS) on the greater curvature of antrum or the lesser curvature of corpus was a sign for no infection with H. pylori (23) .
First we examined sensitivities and specificities of DR and RS for H. pylori-infected or not infected stomach. On the next step we investigated the alterations of the fading of DR and the new expression of RS after H. pylori eradication through five years' observation. Finally we verified the effects of low-dose aspirin on the healing process of stomach after H. pylori infection by univariate regression analysis.
Methods

Study design and subjects
From 2001 to 2008, 12,887 patients underwent endoscopic examination at our hospital. Of these 12,887 patients, patients with (n=100) and without (n=100) H. pylori infection were randomly selected in order to identify the endoscopic features characteristic of H. pylori-infected stomach. These patients did not receive the eradication treatment against H. pylori and low-dose aspirin. Patients who had received antibiotics, proton pump inhibitors, steroids, or NSAIDs were excluded from this study. Patients were also excluded if they had peptic ulcer, underwent partial gastrectomy, consumed alcohol excessively, or had morbid diseases such as liver cirrhosis and uremia, which commonly cause congestive mucosal changes.
We then picked 101 patients who had successful eradication of H. pylori and we observed the alterations of endoscopic features for 5 years (at 6 months, 1 year, and 5 years) after H. pylori eradication in patients who did (n=12) or did not take (n=89) low-dose aspirin. Of note, these 101 patients did not overlap with the former total 200 patients who were analyzed to identify the specific endoscopic feature of H. pylori infection. Written informed consent was obtained from all study subjects prior to the examination.
Diagnosis of H. pylori infection and eradication procedure
A diagnosis of H. pylori infection was reached for cases who had positive results on 2 out of 4 tests: i.e., H. pylori antibody test, urease test (CLO test, Otsuka, Chiyoda-ku, Tokyo, Japan), 13 C-urea breath test, and histological examination (stained with Hematoxylin and Eosin and with Giemsa solution). For the eradication of H. pylori, 1 week of triple therapy with a proton-pump inhibitor, clarithromycin, and amoxicillin was administered twice daily. Residual H. pylori was assessed by a 13 C-urea breath test or a proof of H. pylori antigen in the stool 2 months after eradication.
Endoscopic features of H. pylori infection
At least 2 trained-endoscopists, who experienced more than 5,000 cases of endoscopic examination, independently assessed images at each time point before and after H. pylori eradication. The assessment of images was performed by retrospective evaluation of endoscopic pictures. As the endoscopic findings in the four cases did not match between the two endoscopist, the third trained-endoscopist was joined, discussed and finally reached the conclusion. These endscopists were blinded to the patients' H. pylori status and to taking low-dose aspirin. According to previous studies (22, 23) , we monitored diffuse redness (DR) of the fundic mucosa and reddish streaks (RS) of the antral or corpal mucosa as characteristic feature of H. pylori-positive and -negative stomach, respectively. We first determined the sensitivity and specificity for these 2 features in the cohort of 200 subjects, of which half were H. pylori-negative and half were H. pylori-positive. DR and RS were then assessed at 6 months, 1 year, and 5 years after H. pylori eradication in patients who did or did not receive treatment with low-dose aspirin.
Risk factors affecting the alteration of endoscopic features after H. pylori eradication
We analyzed clinical data to determine risk factors affecting the alteration of endoscopic features after H. pylori eradication. The clinical data evaluated were as follows: gender, age, height (cm), body weight (BW; kg), waist circumference (cm), serum pepsinogen I/II ratio, γ-GTP, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), high sensitivity C-reactive protein (hs-CRP), fasting blood sugar (FBS), HbA1c. In addition, we evaluated a number of patients who were current smokers, or alcohol drinkers (>20 mg/day), or who had diabetes mellitus (DM), hypertension (HT), or old cerebral vascular disease (Old CVD).
Statistical analysis
Statistical analysis was performed using, SPSS 17.0 com- puter software for Windows (SPSS Japan Inc.). Results for continuous variables were expressed as mean ± SD for each patient group. Statistical differences were determined by 2-tailed Student's t-test (for equal variance cases) or Welch's t-test (for unequal variance cases). Non-normally distributed variables were compared using the Mann-Whitney U test. Fisher's exact test was used for analysis of categorical data. In order to identify risk factors to affect the endoscopic changes after H. pylori eradication, multivariate logistic regression analysis was performed. A p-value <0.05 was considered statistically significant.
Results
Specific features of H. pylori infection
We analyzed the relationship between H. pylori infection and the endoscopic feature of diffuse redness (DR) and reddish streaks (RS) in 100 H. pylori-positive subjects and other 100 H. pylori-negative subjects, who were randomly selected and had not received the eradication treatment and low-dose aspirin. As shown in Fig. 1 , DR was observed as a red patch area from the corpus to the fundus of the stomach (Fig. 1A) , whereas RS was evident in the great curvature of the antrum or as scattered linear streaks in the lesser curvature of the lower part of the corpus (Fig. 1D) .
Pathologically, DR represented the prominent inflammatory cell infiltration shown in Fig. 2A and C, and RS was shown by dilated capillaries frequently observed in the stomach not infected with H. pylori or after H. pylori eradication ( Fig. 2B and D) .
There was no significant difference in age or gender between patients with and without H. pylori infection (age: 68±15 vs. 60±18, p=0.07; gender 37/65 vs. 41/59, p=0.56). DR was strongly associated with H. pylori infection (p< 0.00001, Table 1 ); the sensitivity and specificity of DR for predicting H. pylori infection were 96% and 92%, respectively. The reddish streaks were significantly associated with the absence of H. pylori infection (p<0.00001, Table 1 ), its sensitivity and specificity were 100% and 60%, respectively.
Alteration of DR and RS after H. pylori eradication
We then analyzed the other 101 patients who were successful in eradicating H. pylori, 12 patients did and 89 patients did not take low-dose aspirin.
In subjects who did not consumed aspirin (n=89), DR faded over time after H. pylori eradication (Fig. 1A B) . Only 2 of 89 subjects had no DR before eradication, whereas 21% (19/89) and 96% (64/67) of subjects converted to DR negative at 6 months and 1 year, respectively, after H. pylori eradication (p<0.0001 Table 2A ). All subjects (66/ 66) were DR negative after 5 years. Pathological changes were consistent with the macroscopic changes, that is, the prominent inflammatory cell infiltration disappeared after H. pylori eradication (Fig. 2A, B) . No RS was observed in subjects before H. pylori eradication (0/89) (Fig. 1C) , while RS newly appeared over time after eradication (Fig. 1D) . Compared with the fading rate of DR, the expression rate of RS was relatively slow; RS was not expressed at 6 months after H. pylori eradication (0/ 89 vs. 2/89, p=0.15; Table 2A ) but was significantly expressed at 1 year (0/89 vs.7/67, p<0.01). The expression rate of RS reached 68% at 5 years after eradication (Table 2A) . This RS represented newly emerged, dilated capillary vessels as shown in Fig. 2D .
Effects of low-dose aspirin on fading of DR and expression of RS
The fading of DR and the expression of RS appeared to be slower in subjects taking low-dose aspirin (n=12) as compared with subjects who did not (n=89). The rates of DR fading and RS expression showed statistically significant differences at 5 years after H. pylori eradication (0/12 vs.6/6 for DR, p<0.0001, 0/12 vs.3/6, p<0.01 Table 2B ), but did not significally differ at 6 months or 1 year.
When we analyzed association of the fading rate of DR and the intake of low-dose aspirin, the rate of DR fading was significantly lower in subjects taking low-dose aspirin as compared with the no aspirin group at 1 year after eradication (2/10 vs. 64/67, p<0.0001 Table 3 ). DR disappeared in all subjects in both the low-dose aspirin and no aspirin groups 5 years after eradication (Table 3 ). In contrast the expression rate of RS was not strongly associated with aspirin intake at any time point (Table 3) .
Risk factors affecting the alteration of endoscopic features after H. pylori eradication
In order to determine whether low-dose aspirin could be an independent risk factor for modification of endoscopic features after H. pylori eradication, we performed univariate logistic analysis using clinical data. There were no significant differences in clinical data between subjects in the aspirin and no aspirin groups, apart from the rate of old cerebrovascular disease (old CVD) ( Table 4) .
Low-dose aspirin was strongly associated with fading of DR at 1 year after H. pylori eradication (p<0.001, Table 5 ), but not at 6 months (data not shown). There was also an association between DR fading and old CVD, which was the reason for taking low-dose aspirin (p<0.05). By the multivariate logistic regression analysis low-dose aspirin alone was recognized as a risk factor for fading of DR at 1 year after H. pylori eradication (Table 6 ). At 5 years after eradication, all subjects in both the aspirin and no aspirin groups achieved DR-negative gastric mucosa ( Table 3 ), suggesting that low-dose aspirin was not associated with DR fading at 5 years. Intake of low-dose aspirin and old CVD were not associated with RS expression at any time points (data not shown).
Discussion
No consensus evidence has been reached as to whether chronic gastritis related to H. pylori infection can be diagnosed from macroscopic features alone in gastric mucosa (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . Nodular gastritis, however, is characterized endoscopically by micronodules with a smooth surface and is associated with pediatric patients with H. pylori infection (4, 34) . It would be clinically desirable to diagnose H. pylori-associated gastritis simply by endoscopic examination without gastric biopsy.
Based on previous reports (22, 23) we adopted 2 endoscopic features, DR and RS, and confirmed their association with H. pylori-positive and -negative stomach, respectively (Fig. 1) . We confirmed these features were significantly predictive with H. pylori infection status with high sensitivity and specificity (Table 1) .
We also monitored alterations of the gastric mucosa after H. pylori eradication, using these 2 endoscopic features as specific markers for H. pylori infection status. Prior reports have also noted macroscopic changes of the gastric mucosa after H. pylori eradication (4, 22, 23) . Regarding histological examination, a number of studies have described the early healing process of the gastric mucosa after eradication; neutrophils within the mucosa disappeared quickly and were eliminated 6-8 weeks after treatment (35, 36) after this period, the presence of gastric mucosal neutrophils usually indicated treatment failure (37) . One year after H. pylori eradication, a significant improvement of chronic gastritis leading to disappearance of infiltrated neutrophils and superficial epithelial damage was observed in the antral and corpal portions of the stomach (36) (37) (38) (39) (40) . When observed long term, the antral mucosa reverted to nearly normal, whereas degenerated lymphoid aggregates persisted 4 years after eradication (35) and the severity of intestinal metaplasia did not change 7.1 years after eradication (41) .
In this study, we observed that fading of DR occurred at a relatively early stage (6 months after H. pylori eradication) and finally was negative in almost all subjects 1 year later (Table 2A) . DR was pathologically consistent with neutrophil or lymphocyte infiltration in the mucosa, and these findings were disappeared within 12 months after H. pylori eradication in the case of aspirin (-) control group (Table 2A). Aspirin may elicit delayed healing process by inhibition of prostaglandin pathway and slowing down of clearance of neutrophil from the mucosa by enhancing neutrophil chemotaxisis from inside of vessels. Hence, the period of disappearance of DR after H. pylori eradication may prolong from monthly to yearly in aspirin group. In addition, the expression of RS was observed 1 year later in successfully eradicated stomach, and the expression rate of RS reached roughly 70% at 5 years after eradication (Table 2A) . Hence, we concluded that the fading of DR and expression of RS was consistent with the results of prior histological studies and that these can serve as suitable markers for monitoring the healing process of gastric mucosa after H. pylori eradication. Although we acknowledge that it was a relatively small number of patients who took low-dose aspirin and succeeded in eradication of H. pylori, however it may be difficult to increase the number of such patients because most of the patients taking low-dose aspirin to prevent cerebral infarction also receive a medication with a proton pump inhibitor.
In previous studies, a short-term course of aspirin did not cause diffuse histological injury, and the eradication of H. pylori restored gastric adaptation to aspirin (42, 43) . It is generally recognized that H. pylori infection does not worsen mucosal injury with aspirin or NSAIDs because H. pylori infection is associated with increased mucosal levels of prostaglandins (44, 45) . Furthermore, a recent populationbased study determined the effect of H. pylori infection on the development of peptic ulcers in patients with NSAIDs and demonstrated that there was a negative interaction between H. pylori and NSAIDs on duodenal ulcers, suggesting a preventive action of H. pylori against duodenal ulcerogenesis (46) .
To date, there have been no reports regarding the effects of aspirin or NSAIDs on the alteration of endoscopic features after eradication of H. pylori. We reported here that low-dose aspirin delayed the fading of DR and the expression of RS after eradication of H. pylori (Table 2B ). Both alterations were observed only at 5 years after eradication, which was much slower than those observed in subjects that did not consume aspirin.
In addition, univariate regression analysis revealed that aspirin intake was strongly associated and old CVD was weakly associated with fading of DR at 1 year after H. pylori eradication (p<0.001 aspirin and p<0.05 old CVD, Table 5). The multivariate logistic regression analysis revealed low-dose aspirin alone as a risk factor for the slow fading of DR at 1 year after H. pylori eradication (Table 6 ). At 5 years after H. pylori eradication, however, in all subjects, regardless of aspirin intake, the stomach became DR negative (Table 3A) . These results suggest that low-dose aspirin affected the gastric mucosal healing process at around 1 year after eradication; whereas 5 years may be sufficient for gastric mucosal injuries to recover completely even if subjects take low-dose aspirin.
In conclusion, low-dose aspirin delayed improvement of gastric mucosal injury after eradication of H. pylori. More detailed studies, such as an analysis of the relationship between histological changes and macroscopic alteration such as DR and RS, will be needed to definitively establish the effects of low-dose aspirin on gastric mucosal healing after H. pylori eradication.
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